1 Chow, L. Q. M. Head and Neck Cancer. N Engl J Med 382, 60-72, doi:10.1056/NEJMra1715715 (2020).
2 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 33, 3235-3242, doi:10.1200/JCO.2015.61.6995 (2015).
3 Hashibe, M. et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99, 777-789, doi:10.1093/jnci/djk179 (2007).
4 Wyss, A. et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol 178, 679-690, doi:10.1093/aje/kwt029 (2013).
5 McDermott, J. D. & Bowles, D. W. Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. Curr Treat Options Oncol 20, 43, doi:10.1007/s11864-019-0650-5 (2019).
6 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
7 Cho, Y., Milane, L. & Amiji, M. M. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy. Expert Opin Biol Ther 19, 547-560, doi:10.1080/14712598.2019.1602605 (2019).
8 Costa-Pinheiro, P., Montezuma, D., Henrique, R. & Jeronimo, C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics 7, 1003-1015, doi:10.2217/epi.15.56 (2015).
9 Qian, Y. et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 13, 130, doi:10.1186/s13045-020-00958-3 (2020).
10 Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12, 337-365, doi:10.1146/annurev.iy.12.040194.002005 (1994).
11 Fleming, C., Morrissey, S., Cai, Y. & Yan, J. gammadelta T Cells: Unexpected Regulators of Cancer Development and Progression. Trends Cancer 3, 561-570, doi:10.1016/j.trecan.2017.06.003 (2017).
12 Marshall, E. A. et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer 15, 67, doi:10.1186/s12943-016-0551-1 (2016).
13 O'Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16, 151-167, doi:10.1038/s41571-018-0142-8 (2019).
14 Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252, doi:10.1038/32588 (1998).
15 Gardner, A. & Ruffell, B. Dendritic Cells and Cancer Immunity. Trends Immunol 37, 855-865, doi:10.1016/j.it.2016.09.006 (2016).
16 Hilligan, K. L. & Ronchese, F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell Mol Immunol 17, 587-599, doi:10.1038/s41423-020-0465-0 (2020).
17 Mullard, A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12, 489-492, doi:10.1038/nrd4066 (2013).
18 McCune, J. S. Rapid Advances in Immunotherapy to Treat Cancer. Clin Pharmacol Ther 103, 540-544, doi:10.1002/cpt.985 (2018).
19 Predina, J. et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 110, E415-424, doi:10.1073/pnas.1211850110 (2013).
20 Wang, L. et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98, 1458-1466, doi:10.3324/haematol.2012.071340 (2013).
21 Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18, 6580-6587, doi:10.1158/1078-0432.CCR-12-1362 (2012).
22 Motz, G. T. & Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 39, 61-73, doi:10.1016/j.immuni.2013.07.005 (2013).
23 Khalil, A. M. et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 106, 11667-11672, doi:10.1073/pnas.0904715106 (2009).
24 Mathy, N. W. & Chen, X. M. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem 292, 12375-12382, doi:10.1074/jbc.R116.760884 (2017).
25 Bartonicek, N., Maag, J. L. & Dinger, M. E. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer 15, 43, doi:10.1186/s12943-016-0530-6 (2016).
26 Kornfeld, J. W. & Bruning, J. C. Regulation of metabolism by long, non-coding RNAs. Front Genet 5, 57, doi:10.3389/fgene.2014.00057 (2014).
27 Vitiello, M., Tuccoli, A. & Poliseno, L. Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol (Dordr) 38, 17-28, doi:10.1007/s13402-014-0180-x (2015).
28 Fu, X., Ravindranath, L., Tran, N., Petrovics, G. & Srivastava, S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 25, 135-141, doi:10.1089/dna.2006.25.135 (2006).
29 Walsh, A. L., Tuzova, A. V., Bolton, E. M., Lynch, T. H. & Perry, A. S. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? Trends Mol Med 20, 428-436, doi:10.1016/j.molmed.2014.03.005 (2014).
30 Warrick, J. I. et al. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol 27, 609-620, doi:10.1038/modpathol.2013.169 (2014).
31 Bhan, A. et al. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol 425, 3707-3722, doi:10.1016/j.jmb.2013.01.022 (2013).
32 Geng, Y. J., Xie, S. L., Li, Q., Ma, J. & Wang, G. Y. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 39, 2119-2128, doi:10.1177/147323001103900608 (2011).
33 Kim, K. et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32, 1616-1625, doi:10.1038/onc.2012.193 (2013).
34 Li, D. et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol 182, 64-70, doi:10.1016/j.ajpath.2012.08.042 (2013).
35 Nakagawa, T. et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochem Biophys Res Commun 436, 319-324, doi:10.1016/j.bbrc.2013.05.101 (2013).
36 Fatica, A. & Bozzoni, I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15, 7-21, doi:10.1038/nrg3606 (2014).
37 Yu, W. D., Wang, H., He, Q. F., Xu, Y. & Wang, X. C. Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol 233, 6518-6523, doi:10.1002/jcp.26568 (2018).
38 Pandya, P. H., Murray, M. E., Pollok, K. E. & Renbarger, J. L. The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res 2016, 4273943, doi:10.1155/2016/4273943 (2016).
39 Zhou, D. et al. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal 26, 192-197, doi:10.1016/j.cellsig.2013.11.004 (2014).
40 Huang, Z. et al. Identification of Differentially Expressed Long Non-coding RNAs in Polarized Macrophages. Sci Rep 6, 19705, doi:10.1038/srep19705 (2016).
41 Ye, Y. et al. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem 119, 2951-2963, doi:10.1002/jcb.26509 (2018).
42 Fang, P. et al. LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun 25, 99-109, doi:10.1177/1753425919827632 (2019).
43 Ou, Z. L. et al. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis. RNA Biol 16, 1592-1603, doi:10.1080/15476286.2019.1649585 (2019).
44 Wei, M. F., Gu, Z. S., Zheng, L. L., Zhao, M. X. & Wang, X. J. Long non-coding RNA GAS5 promotes natural killer cell cytotoxicity against gastric cancer by regulating miR-18a. Neoplasma 67, 1085-1093, doi:10.4149/neo_2020_191014N1034 (2020).
45 Zhang, Y., Li, X., Zhang, J. & Liang, H. Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis. Cancer Lett 474, 63-73, doi:10.1016/j.canlet.2019.12.038 (2020).
46 Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37, 773-782, doi:10.1038/s41587-019-0114-2 (2019).
47 Bauml, J. et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol 35, 1542-1549, doi:10.1200/JCO.2016.70.1524 (2017).
48 Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156-167, doi:10.1016/S0140-6736(18)31999-8 (2019).
49 Mehra, R. et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119, 153-159, doi:10.1038/s41416-018-0131-9 (2018).
50 Pai, S. I. et al. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). J Immunother Cancer 7, 96, doi:10.1186/s40425-019-0578-0 (2019).
51 Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17, 956-965, doi:10.1016/S1470-2045(16)30066-3 (2016).
52 Rizvi, H. et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 36, 633-641, doi:10.1200/JCO.2017.75.3384 (2018).
53 Liu, A. N., Qu, H. J., Yu, C. Y. & Sun, P. Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. J Cell Mol Med 22, 4034-4044, doi:10.1111/jcmm.13483 (2018).
54 Vishnubalaji, R., Shaath, H., Elkord, E. & Alajez, N. M. Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFbeta and focal adhesion kinase (FAK) signaling. Cell Death Discov 5, 109, doi:10.1038/s41420-019-0190-6 (2019).
55 Eble, J. A. & Niland, S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis 36, 171-198, doi:10.1007/s10585-019-09966-1 (2019).
56 Pickup, M. W., Mouw, J. K. & Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15, 1243-1253, doi:10.15252/embr.201439246 (2014).
57 Walker, C., Mojares, E. & Del Rio Hernandez, A. Role of Extracellular Matrix in Development and Cancer Progression. Int J Mol Sci 19, doi:10.3390/ijms19103028 (2018).
58 Qing, L. et al. Extracellular Matrix-Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer. Onco Targets Ther 13, 12521-12538, doi:10.2147/OTT.S284167 (2020).
59 Tibshirani, R. The lasso method for variable selection in the Cox model. Stat Med 16, 385-395, doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3 (1997).
60 Cui, Y. et al. LncRNA linc00460 sponges miR-1224-5p to promote esophageal cancer metastatic potential and epithelial-mesenchymal transition. Pathol Res Pract 216, 153026, doi:10.1016/j.prp.2020.153026 (2020).
61 Dong, Y. & Quan, H. Y. Downregulated LINC00460 inhibits cell proliferation and promotes cell apoptosis in prostate cancer. Eur Rev Med Pharmacol Sci 23, 6070-6078, doi:10.26355/eurrev_201907_18420 (2019).
62 Zhao, H., Wang, Y. & Ren, X. Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. Biosci Rep 39, doi:10.1042/BSR20182443 (2019).
63 Jiang, Y. et al. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus. J Exp Clin Cancer Res 38, 365, doi:10.1186/s13046-019-1364-z (2019).
64 Cai, W. Y. et al. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis. J Cell Biochem 119, 8249-8259, doi:10.1002/jcb.26836 (2018).
65 Li, Z. et al. Identification of immune-related lncRNAs to improve the prognosis prediction for patients with papillary thyroid cancer. Biosci Rep 41, doi:10.1042/BSR20204086 (2021).
66 Tan, J. et al. Overexpression of novel long intergenic noncoding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer. Oncol Rep 44, 1489-1501, doi:10.3892/or.2020.7712 (2020).
67 Liu, Y. et al. Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP. J Cancer 12, 1660-1668, doi:10.7150/jca.47344 (2021).
68 Necula, L. et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 25, 2029-2044, doi:10.3748/wjg.v25.i17.2029 (2019).
69 Zhang, E. et al. A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1. Genome Biol 19, 154, doi:10.1186/s13059-018-1523-0 (2018).
70 Zhuo, W. et al. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. Gastroenterology 156, 676-691 e611, doi:10.1053/j.gastro.2018.10.054 (2019).
71 Zhang, C. et al. A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clin Transl Med 10, e156, doi:10.1002/ctm2.156 (2020).
72 Zhou, R. et al. A stroma-related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer. J Cell Mol Med 24, 3229-3241, doi:10.1111/jcmm.14999 (2020).
73 Huan, L. et al. Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response. Mol Cancer 19, 11, doi:10.1186/s12943-019-1122-z (2020).
74 Yang, Q. et al. lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCF(beta-TRCP)-Mediated Degradation of NRF2 in Pancreatic Cancer. Mol Ther Nucleic Acids 19, 974-985, doi:10.1016/j.omtn.2019.11.035 (2020).
75 Gu, N. et al. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis. Aging (Albany NY) 11, 10266-10283, doi:10.18632/aging.102455 (2019).
76 Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book 39, 147-164, doi:10.1200/EDBK_240837 (2019).
77 Wei, B., Kong, W., Mou, X. & Wang, S. Comprehensive analysis of tumor immune infiltration associated with endogenous competitive RNA networks in lung adenocarcinoma. Pathol Res Pract 215, 159-170, doi:10.1016/j.prp.2018.10.032 (2019).
78 Heward, J. A. & Lindsay, M. A. Long non-coding RNAs in the regulation of the immune response. Trends Immunol 35, 408-419, doi:10.1016/j.it.2014.07.005 (2014).
79 Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity 50, 1132-1148, doi:10.1016/j.immuni.2019.04.011 (2019).
80 Hetta, H. F. et al. T follicular helper and T follicular regulatory cells in colorectal cancer: A complex interplay. J Immunol Methods 480, 112753, doi:10.1016/j.jim.2020.112753 (2020).
81 Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular Helper T Cells. Annu Rev Immunol 34, 335-368, doi:10.1146/annurev-immunol-041015-055605 (2016).
82 Hetta, H. F. et al. Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology. J Gastroenterol Hepatol 30, 1543-1551, doi:10.1111/jgh.12936 (2015).
83 Mehta, M. et al. Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol 161, 3161-3169, doi:10.1007/s00705-016-3015-4 (2016).
84 Zahran, A. M. et al. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomark 22, 587-595, doi:10.3233/CBM-181368 (2018).
85 Zahran, A. M. et al. Increased frequency and FOXP3 expression of human CD8(+)CD25(High+) T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma. Hum Immunol 80, 510-516, doi:10.1016/j.humimm.2019.03.014 (2019).
86 Kawada, J. I. et al. Immune cell infiltration landscapes in pediatric acute myocarditis analyzed by CIBERSORT. J Cardiol 77, 174-178, doi:10.1016/j.jjcc.2020.08.004 (2021).
87 Hugo, W. et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165, 35-44, doi:10.1016/j.cell.2016.02.065 (2016).
88 Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211, doi:10.1126/science.aad0095 (2015).
89 Geeleher, P., Cox, N. & Huang, R. S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 9, e107468, doi:10.1371/journal.pone.0107468 (2014).